
- BioPharm International-08-01-2018
- Volume 31
- Issue 8
FDA Seeks to Revive Quality Metrics Initiative
The agency is asking firms to discuss internal quality metrics efforts as part of the approval process for new medical products.
FDA has struggled for several years to establish a program for collecting data from biopharmaceutical manufacturers that can measure how well a firm produces high-quality products on a consistent basis. Now after months of inaction on advancing a proposed quality metrics initiative, the agency appears to be starting over by asking firms to discuss internal quality metrics efforts as part of the approval process for new medical products. FDA also is proposing that manufacturers invite agency staffers to visit sites to examine more closely a firm’s quality measurement program.
FDA’s quality metrics initiative emerged several years ago as part of agency efforts to encourage industry investment in quality manufacturing systems able to reduce product defects that could lead to drug shortages and recalls. A 2015 draft guidance from the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) proposed to collect data on manufacturing operations and product attributes that could help measure how well a firm was able to meet quality standards. In response to multiple comments from industry, FDA issued a
The negative comments to these proposals reflect wide disparities in how pharma companies individually measure and track manufacturing operations and product quality. Firms raised concerns that FDA would make the reporting program mandatory, instead of voluntary, and that it was particularly difficult to assess a firm’s “quality culture,” involving how management encouraged and supported methods to quality production. Trade organizations asserted that the proposed metrics program would require substantial industry resources and significant operational changes that could undermine other quality improvement efforts. And there was strong opposition to indications that FDA might publicly disclose metrics data-whether to reward high performers or to encourage others to invest more in quality improvement.
Metrics on hold
Since then, FDA has been quiet on the metrics issue, even as agency leaders have highlighted the importance of improving drug quality and adopting continuous manufacturing systems. At the ISPE Quality Manufacturing conference in June 2018, industry representatives discussed efforts to advance metrics measurement methods, and experts from the University of St. Gallen provided an update on their model for using metrics to drive continuous improvement and greater efficiencies in pharmaceutical production.
Yet, FDA had little new to report. Tara Gooen-Bizjak, senior science policy advisor in CDER’s Office of Pharmaceutical Quality, had the unhappy task of reporting that “active discussions” about quality metrics were continuing at the agency, and that metrics data were regarded as important for improving quality. She acknowledged that most manufacturers use quality metrics as part of process validation, lifecycle management, and pharmaceutical quality assessment. But she could not say when FDA might issue revised guidance or further proposals on the metrics initiative.
FDA’s recent announcement indicates that the agency is taking a fresh look at how manufacturers use metrics in their internal operations to inform its plan for collecting quality measures. A new Quality Metrics Feedback Program seeks to learn more about quality metrics activities across the industry. Manufacturers of new drugs are encouraged
In addition, a new
FDA seeks several firms to apply by June 2019 to participate in these voluntary programs. In announcing the new initiatives, the agency says it seeks to “continue learning about the advantages and challenges” companies have experienced with metrics programs in order to inform policy development. One possibility is that metrics data will help devise a more risk-based inspection program that offers decreased establishment inspections for high-quality facilities. FDA also hopes to better identify situations likely to experience supply disruptions. More information on FDA manufacturing quality initiatives can be found at
Article Details
Orignially posted online at BioPharmInternational.com July 2, 2018.
Print publication:
BioPharm International
Vol. 31, No. 8
August 2018
Pages: 8-9
Citation
When referring to this article, please cite it as J. Wechsler, "FDA Seeks to Revive Quality Metrics Initiative," BioPharm International 31 (8) 2018.
Articles in this issue
about 7 years ago
The Search for Next-Gen Expression Systemsabout 7 years ago
FDA Is Not Playing Games with Biosimilarsabout 7 years ago
Expectations for Residual Impurity Analysis Continue to Riseabout 7 years ago
E&L Risk Assessment for Biologic Drug Productsabout 7 years ago
Submitting Extractables and Leachables Data to Regulatorsabout 7 years ago
A New Paradigm in Drug Developmentabout 7 years ago
Maintaining Cell Line Integrityabout 7 years ago
BioPharm International, August 2018 Issue (PDF)Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.